Adds bempedoic acid to standard cholesterol medicines after a heart attack
Tests adding bempedoic acid to atorvastatin and ezetimibe in adults with acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Key facts
- Where
- Lahore, PakistanSee the site
- Phase
- Phase 4
Where in Pakistan
- Punjab Institute of CardiologyLahore, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Punjab Institute of Cardology
- Trial code
- NCT07508254
- Record updated
- 9 April 2026
- Original description
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.Read full original descriptionShow less
Triple (Atorvastatin, Ezetimibe, and Bempedoic Acid) Versus Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome: A Randomized Controlled Trial
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.
The main questions it aims to answer are:
* Does triple therapy result in greater reduction in LDL-C compared to dual therapy? * What adverse effects occur in participants receiving triple therapy?
Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels.
Participants will:
* Receive either dual or triple lipid-lowering therapy for 3 months * Attend regular follow-up visits for clinical assessment and laboratory testing * Undergo lipid profile evaluation at baseline and at the end of the study
Inclusion: Must be older than 18 years, male or female; Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized; Eligible for high-intensity statin therapy (atorvastatin); Patients can provide written informed consent; Patients will be eager to cooperate with study drugs and follow-up visits.
Exclusion: Intolerance or hypersensitivity to study drugs; Liver or ALT/AST greater than three times the upper normal; Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m²; Gout with frequent bouts or severe hyperuricemia; Pregnancy/lactation.